Sector News

Merck KGaA appoints Allan Gabor as managing director in China

December 12, 2017
Life sciences

Merck KGaA said on Tuesday that Allan Gabor will succeed Alasdair Jelfs as managing director for the company in China as of Feb. 1, 2018.

The German company said Mr. Gabor would also take over operational responsibility for the performance materials business in China.

Additionally, Mr. Gabor will become a permanent member of the performance materials leadership team, Merck KGaA said.

Mr. Jelfs take up duties at company headquarters in Darmstadt, Germany, the company said.

Mr. Gabor joined Merck KGaA in 2013, and is currently head of the biopharma business in Asia, including China. Prior to joining the company, Mr. Gabor was head of Pfizer in China.

By Marc Navarro Gonzalez

Source: Dow Jones Newswires via Fox Business

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend